Welcome To The Stem Cell Therapeutics HUB On AGORACOM

Stem Cell is a public biotechnology company focused on the development and commercialization of drug-based therapies to treat central nervous system diseases.

Free
Message: NR: Stem Cell Therapeutics Corp. Announces the Issuance of United States Patent

Stem Cell Therapeutics Corp. Announces the Issuance of United States Patent

CALGARY, ALBERTA, Jun 08, 2010 (MARKETWIRE via COMTEX News Network) --

Stem Cell Therapeutics Corp. (TSX VENTURE: SSS) ("SCT" or the "Company") is pleased to announce today that it has been granted U.S. Patent 7,704,737 entitled, "Oligodendrocyte Production from Multipotent Neural Stem Cells". The claims cover the use of granulocyte macrophage colony stimulating factor (GM-CSF) for producing oligodendrocytes from multipotent neural stem cells in culture. This is the second patent to issue in this patent family.

Dr. Alan Moore, President and CEO, commented as follows:

"The technology covered by this patent is of potential use as cell transplant therapy for treating demyelinating diseases resulting from oligodendrocyte loss or damage, such as multiple sclerosis and spinal cord injury. This patent expands and adds value to SCT's overall intellectual property portfolio."

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public biotechnology company (TSX VENTURE: SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair brain and nerve function lost due to disease or injury. The Company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.


Contacts:
Stem Cell Therapeutics Corp.
Alan Moore, PhD
President and CEO
403-245-5495 ext.224
[email protected]

Stem Cell Therapeutics Corp.
Angelika Goncalves DaSilva
Operations Manager
403-245-5495 ext. 230
[email protected]
www.stemcellthera.com


SOURCE: Stem Cell Therapeutics Corp.

Share
New Message
Please login to post a reply